AbbVie completes acquisition of Landos Biopharma
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Further strengthens BaseLaunch's global pharma industry partnerships
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Subscribe To Our Newsletter & Stay Updated